Citadel Advisors’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-15,600
| Closed | -$337K | – | 16089 |
|
|
2022
Q4 | $337K | Buy |
15,600
+2,700
| +21% | +$57.1K | ﹤0.01% | 9068 |
|
|
2022
Q3 | $250K | Sell |
12,900
-1,000
| -7% | -$20.7K | ﹤0.01% | 9969 |
|
|
2022
Q2 | $276K | Buy |
13,900
+7,000
| +101% | +$185K | ﹤0.01% | 9982 |
|
|
2022
Q1 | $206K | Sell |
6,900
-11,600
| -63% | -$340K | ﹤0.01% | 11471 |
|
|
2021
Q4 | $431K | Sell |
18,500
-8,600
| -32% | -$229K | ﹤0.01% | 10038 |
|
|
2021
Q3 | $846K | Buy |
27,100
+6,700
| +33% | +$207K | ﹤0.01% | 8562 |
|
|
2021
Q2 | $718K | Buy |
20,400
+9,100
| +81% | +$296K | ﹤0.01% | 9197 |
|
|
2021
Q1 | $398K | Sell |
11,300
-26,800
| -70% | -$989K | ﹤0.01% | 10189 |
|
|
2020
Q4 | $1.43M | Sell |
38,100
-78,400
| -67% | -$2.85M | ﹤0.01% | 6043 |
|
|
2020
Q3 | $3.89M | Buy |
116,500
+107,900
| +1,255% | +$3.14M | ﹤0.01% | 3532 |
|
|
2020
Q2 | $228K | Buy |
+8,600
| New | +$203K | ﹤0.01% | 8344 |
|
|
2016
Q1 | – | Sell |
-157
| Closed | -$2K | – | 8294 |
|
|
2015
Q4 | $2K | Sell |
157
-46
| -23% | -$476 | ﹤0.01% | 8587 |
|
|
2015
Q3 | $3K | Buy |
203
+53
| +35% | +$1.33K | ﹤0.01% | 8709 |
|
|
2015
Q2 | $5K | Buy |
150
+10
| +7% | +$336 | ﹤0.01% | 8546 |
|
|
2015
Q1 | $5K | Buy |
140
+107
| +324% | +$4.51K | ﹤0.01% | 8329 |
|
|
2014
Q4 | $1K | Sell |
33
-7
| -18% | -$307 | ﹤0.01% | 8427 |
|
|
2014
Q3 | $2K | Buy |
+40
| New | +$2.3K | ﹤0.01% | 8005 |
|
|
2014
Q2 | – | Sell |
-87
| Closed | -$7K | – | 8415 |
|
|
2014
Q1 | $7K | Buy |
87
+7
| +9% | +$637 | ﹤0.01% | 7601 |
|
|
2013
Q4 | $6K | Sell |
80
-580
| -88% | -$42.5K | ﹤0.01% | 6807 |
|
|
2013
Q3 | $62K | Buy |
660
+370
| +128% | +$48.2K | ﹤0.01% | 5666 |
|
|
2013
Q2 | $36K | Buy |
+290
| New | +$30.2K | ﹤0.01% | 5819 |
|
Other funds holding ALBO
Citadel Advisors's ALBO Position: Q1 2023 in Review
Citadel Advisors sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 2,169 shares — an estimated $46.9K sold.
Citadel Advisors first reported a position in ALBO in Q2 2013 and held it in 24 quarters. The position peaked at $4.83M in Q3 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Citadel Advisors reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 2,169 Albireo Pharma Inc shares in Q1 2023, an estimated $46.9K.
- Citadel Advisors first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 24 quarters.
- Citadel Advisors's Albireo Pharma Inc position peaked at $4.83M in Q3 2022.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.